Main >

>
Revolutionizing Brain Cancer Treatment: NeOnc Introduces First Non-Invasive Intranasal Drug Delivery for Brain Cancer
NeOnc, a biotech company helmed by Dr. Thomas Chen, brings the first non-invasive intranasal drug delivery for brain cancer into the spotlight. With this revolutionary treatment, NeOnc is poised to change the way the world looks at brain cancer treatment.
Approximately 24,000 people are diagnosed with a primary brain tumor every year in the United States. The diagnosis often means a battery of invasive tests, followed by treatments that range from radiation and chemotherapy to craniotomies, which involve surgically opening up the skull.
Patients struggle not just with invasive procedures but also with the lack of innovation. Glioblastoma research has not significantly improved patient survival, for example, despite the significant number of cases diagnosed each year.

NeOnc’s Executive Chairman Amir Heshmatpour with CEO and CSO Dr. Thomas Chen
“One of our problems is just getting the drug or the biologics into the patient,” says Dr. Chen. And it’s a significant problem, with the blood-brain barrier being the biggest hurdle to overcome.
This natural barrier is meant to insulate the brain from pathogens. But when it comes to brain cancer, the very thing meant to protect the organ makes it more difficult to treat what’s harming it.
“We know there are a lot of companies that are developing new treatments for brain cancer, new drugs, etc. But the main thing is how do we get the drug to the target?”
That question fueled Dr. Chen and the whole team at NeOnc to focus not on how to make the drugs better able to permeate the blood-brain barrier but how to bypass it altogether. The answer is a nasal-brain delivery system.
“What you’re doing is inhaling the compound and letting your cranial nerves deliver it to the brain.” This intranasal drug delivery system would allow patients to get the treatment they need at home.
The therapy, the first of its kind, is in Phase II trials and enrolling human test subjects. It already shows promise. Dr. Chen claims it’s helping to prolong the life of some of his patients.
It is important to note that Dr. Chen is currently treating patients with recurrent brain cancer, offering people who have already failed standard of care therapy but failed. This treatment gives these patients another opportunity to combat their brain cancer.
So, what are the next steps for this potentially revolutionary brain cancer treatment? “Once we’re done with Phase IIa, depending on the data, (the FDA) will tell us whether we do a Phase III or a Phase IIb.”
The drug currently has a “fast track” designation, which will be expedited through the approval process, as often happens with new drugs or biologics intended to treat serious conditions.
“The results will speak for themselves,” says Amir Heshmatpour, the company’s finance expert, about the biotech IPO 2024 option. Those words will also apply to the inventive new brain cancer treatment slowly making its way to the general public.
ABOUT LA WEEKLY
The LA Weekly was founded in 1978 and is a free weekly newspaper in Los Angeles, California. The paper covers Los Angeles music, arts, film, theater, culture, concerts, and events. The paper is known for presenting independent reporting on topics important to the LA community. The staff consists of Pulitzer prize-winning journalists and has been the recipient of many awards and recognitions in the new publication field.
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a privately held clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier.
The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status.
The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit neonc.com.
NeOnc Company Contact:
Patrick Walters, COO
NeOnc Technologies Holdings, Inc.
NeOnc Investor Relations:
Ron Both
CMA Investor Relations
Tel (949) 432-7566
NeOnc Media & ESG Contact:
Tim Randall
CMA Media Relations
Tel (949) 432-7572